TiCAB试验:多支或单支动脉搭桥术后替格瑞洛单药与阿司匹林比较
该研究为TiCAB试验的事后非随机分析,纳入1753例CABG患者(MAG 998例,SAG 755例),比较替格瑞洛与阿司匹林在术后1年的复合终点及出血事件。结果显示,无论MAG或SAG,替格瑞洛与阿司匹林在主要复合终点(心血管死亡、非致死性心梗、卒中或再次血运重建)及大出血方面均无显著差异。
要点
- MAG患者1年主要复合终点替格瑞洛7.2% vs 阿司匹林7.9%,HR 0.90(95%CI 0.57-1.43),P=0.66。
- SAG患者1年主要复合终点替格瑞洛12.3% vs 阿司匹林8.6%,HR 1.47(95%CI 0.93-2.31),P=0.10。
- MAG和SAG患者中,替格瑞洛与阿司匹林的大出血发生率均无显著差异。
核心结论
- 在TiCAB试验中,无论多支动脉搭桥或单支动脉搭桥,替格瑞洛单药与阿司匹林相比未影响术后1年心血管死亡、非致死性心梗、卒中或再次血运重建率,也未影响出血率。
研究设计与样本
- TiCAB试验(NCT01755520)的事后非随机分析,共纳入1753例CABG患者,其中998例接受MAG,755例接受SAG,比较替格瑞洛与阿司匹林的事件率。
主要发现
- MAG患者1年主要复合终点替格瑞洛组7.2% vs 阿司匹林组7.9%,HR 0.90(95%CI 0.57-1.43),P=0.66。
- SAG患者1年主要复合终点替格瑞洛组12.3% vs 阿司匹林组8.6%,HR 1.47(95%CI 0.93-2.31),P=0.10。
- MAG患者大出血替格瑞洛组2.6% vs 阿司匹林组2.7%,HR 0.95(95%CI 0.44-2.05),P=0.90。
- SAG患者大出血替格瑞洛组5.8% vs 阿司匹林组4.0%,HR 1.49(95%CI 0.77-2.89),P=0.24。
- 心血管死亡、心梗、卒中、再次血运重建和全因死亡在MAG和SAG两个治疗组间均相似。
临床怎么用
- 对于CABG术后患者,无论采用MAG或SAG,替格瑞洛单药与阿司匹林在1年缺血和出血事件上无显著差异,临床决策需个体化。
局限性
- 该分析为TiCAB试验的事后非随机分析,可能存在混杂偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: We evaluated the effect of ticagrelor monotherapy on outcomes after multiple arterial grafting (MAG) or single arterial grafting (SAG) in coronary artery bypass grafting (CABG). METHODS: In a post hoc, non-randomized analysis of the TiCAB (Ticagrelor in CABG; ClinicalTrials.gov NCT01755520) trial, we compared event rates for ticagrelor versus aspirin in patients undergoing MAG and SAG. Primary outcome was the composite of cardiovascular death, non-fatal myocardial infarction (MI), stroke or repeat revascularization 1 year after CABG. Secondary outcomes included individual components of the primary end point, all-cause death and bleeding. RESULTS: Among 1753 patients, 998 patients underwent MAG and 755 patients underwent SAG. There was no significant difference in the 1-year primary composite outcome for ticagrelor versus aspirin with MAG [7.2% vs 7.9%; hazard ratio (HR) 0.90, 95% confidence interval (CI) 0.57-1.43; P = 0.66] or SAG (12.3% vs 8.6%; HR 1.47, 95% CI 0.93-2.31; P = 0.10). Event rates for cardiovascular death, MI, stroke, repeat revascularization and all-cause death were similar for both treatment groups with MAG and SAG. No significant difference in major bleeding was observed for ticagrelor versus aspirin with MAG (2.6% vs 2.7%; HR 0.95, 95% CI 0.44-2.05; P = 0.90) or SAG (5.8% vs 4.0%; HR 1.49, 95% CI 0.77-2.89; P = 0.24). CONCLUSIONS: In patients undergoing either MAG or SAG in the TiCAB trial, ticagrelor monotherapy compared with aspirin did not affect the rate of cardiovascular death, non-fatal MI, stroke or repeat revascularization, or the rate of bleeding, at 1 year after CABG.
引用
- Sandner SE, Schunkert H, Kastrati A, et al. Ticagrelor monotherapy versus aspirin in patients undergoing multiple arterial or single arterial coronary artery bypass grafting: insights from the TiCAB trial. Eur J Cardiothorac Surg. 2020. PMID: 31750899. doi:10.1093/ejcts/ezz313
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。